Article
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Frontiers in immunology - 1 Jan 2021
Xu Qian, Zhang Xue, Huang Miao, Dai Xin, Gao Jing, Li Song, Sheng Lei, Huang Kai, Wang Jian, Liu Lian
Abstract excerpt
Background: Immune checkpoint inhibitors (ICIs) have improved survival for advanced wild-type non-small cell lung cancer (NSCLC) significantly, but few studies compared single ICI (SICI)-based treatments and double ICIs (DICI)-based treatments. We summarized the general efficacy of ICI-related treatments, compared the efficacy and safety of SICI-based [programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.